Cellectis S.A. Stock Forecast
Stronger technical forecast for Cellectis S.A. stock price after Tuesday trading.
(Updated on Mar 28, 2023)
The Cellectis S.A. stock price gained 2.26% on the last trading day (Tuesday, 28th Mar 2023), rising from $1.99 to $2.04. During the last trading day the stock fluctuated 1.98% from a day low at $2.02 to a day high of $2.06. The price has risen in 6 of the last 10 days and is up by 2.78% over the past 2 weeks. Volume fell on the last day by -106 thousand shares and in total, 7 thousand shares were bought and sold for approximately $13.53 thousand. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.
Build a recession-proof portfolio with your existing stocks. Register to free live event. Ad
The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -33.17% during the next 3 months and, with a 90% probability hold a price between $0.402 and $1.82 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.
CLLS Signals & Forecast
There are mixed signals in the stock today. The Cellectis S.A. stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term moving average at $2.14. On a fall, the stock will find some support from the short-term average at $1.99. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. A sell signal was issued from a pivot top point on Friday, January 13, 2023, and so far it has fallen -47.01%. Further fall is indicated until a new bottom pivot has been found. Volume fell during the last trading day while the price increased. This causes a divergence and may be considered as an early warning, but it may not be. The very low volume increases the risk and reduces the other technical signals issued. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD).
Support, Risk & Stop-loss for Cellectis S.A. stock
Cellectis S.A. finds support from accumulated volume at $1.99 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
This stock has average movements during the day, but be aware of low or falling volume as this increases the risk. During the last day, the stock moved $0.0400 between high and low, or 1.98%. For the last week the stock has had daily average volatility of 4.69%.
Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.
Trading Expectations (CLLS) For The Upcoming Trading Day Of Wednesday 29th
For the upcoming trading day on Wednesday, 29th we expect Cellectis S.A. to open at $2.04, and during the day (based on 14 day Average True Range), to move between $1.90 and $2.17, which gives a possible trading interval of +/-$0.132 (+/-6.49%) up or down from last closing price. If Cellectis S.A. takes out the full calculated possible swing range there will be an estimated 12.97% move between the lowest and the highest trading price during the day.
Since the stock is closer to the support from accumulated volume at $1.99 (2.21%) than the resistance at $2.25 (10.57%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..
Is Cellectis S.A. stock A Buy?
Cellectis S.A. holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock. We have upgraded our analysis conclusion for this stock since the last evaluation from a Strong Sell to a Sell candidate.
Current score: -3.305 Open Broker Account
Sell Candidate UpgradedPredicted Opening Price for Cellectis S.A. of Wednesday, March 29, 2023
The predicted opening price is based on yesterday's movements between high, low, and closing price.
| Fair opening price March 29, 2023 | Current price |
|---|---|
| $2.04 | $2.04 (Undervalued) |
Remember To Visit Our YouTube Channel
Trading levels for CLLS
Fibonacci Support & Resistance Levels
| Level | Price | |||
|---|---|---|---|---|
| Resistance | R3 | 2.08 | 2.13 % | |
| R2 | 2.06 | 1.38 % | ||
| R1 | 2.05 | 0.91 % | ||
| Current price: | 2.04 | |||
| Support | S1 | 2.02 | -0.587 % | |
| S2 | 2.01 | -1.05 % | ||
| S3 | 2.00 | -1.80 % |
Accumulated Volume Support & Resistance Levels
| Level | Price | |||
|---|---|---|---|---|
| Resistance | R3 | 2.51 | 23.34 % | |
| R2 | 2.38 | 16.95 % | ||
| R1 | 2.25 | 10.57 % | ||
| Current price | 2.04 | |||
| Support | S1 | 1.99 | -2.21% | |
| S2 | 1.95 | -4.18% | ||
| S3 | 1.90 | -6.88% |
FAQ
Click here for our free guide on how to buy Cellectis S.A. Stock.
About Cellectis S.A.
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALL... CLLS Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
